On ECHEMI
Home > Drugs > Duloxetine hydrochloride Registered Holders
Duloxetine hydrochloride structure

Duloxetine hydrochloride structure

Duloxetine hydrochloride

In addition, duloxetine recipients experienced significantly greater increases in their average voiding interval than placebo recipients (15.0–20.4 versus 1.7–8.5 minutes). The most commonly observed adverse events associated with duloxetine therapy are nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating. As with other 5-HT reuptake inhibitors, duloxetine is contraindicated in patients taking MAO inhibitors. Additionally, it is contraindicated

Find 87 Related Holders

MOEHS IBERICA SL
United States United States

API Registration Country

API Active
AJANTA PHARMA LTD
United States United States

API Registration Country

API Active
SHODHANA LABORATORIES PRIVATE LTD
United States United States

API Registration Country

API Active
INIST ST CO.,LTD.
Japan Japan

API Registration Country

API Active
SHANKUS PHARMA PRIVATE LTD
United States United States

API Registration Country

API Active
Sun Pharmaceutical Industries Ltd
United States United States

API Registration Country

API Active
SCI PHARMTECH INC
United States United States

API Registration Country

API Active
ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD
United States United States

API Registration Country

API Active
Zhejiang Liaoyuan Pharmaceutical Co., Ltd.
European Union European Union

API Registration Country

API Active
SHODHANA LABORATORIES LTD
United States United States

API Registration Country

API Inactive
Recommended Suppliers of Duloxetine hydrochloride
View 94 Suppliers Request for Quotation
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.